DPP4 and type 2 diabetes mellitus: In general, studies of DPP-4 inhibitors have shown similar or better safety than placebo and other antidiabetic drugs in older adults with type 2 diabetes, but these safety data are mainly based on short-term outcomes like hypoglycaemic events and acute adverse events.